[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]

Pharm Unserer Zeit. 2009;38(4):320-8. doi: 10.1002/pauz.200900321.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Biotransformation
  • Clopidogrel
  • Humans
  • Piperazines / adverse effects
  • Piperazines / pharmacokinetics*
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prasugrel Hydrochloride
  • Prodrugs
  • Purinergic P2 Receptor Antagonists*
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Thiophenes / adverse effects
  • Thiophenes / pharmacokinetics*
  • Thiophenes / pharmacology*
  • Thiophenes / therapeutic use
  • Thrombosis / blood
  • Thrombosis / prevention & control*
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / pharmacology
  • Ticlopidine / therapeutic use

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Prodrugs
  • Purinergic P2 Receptor Antagonists
  • Thiophenes
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine